证券代码：603301 证券简称：振德医疗 公告编号：2025-043 振德医疗用品股份有限公司 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案已经公司第四届董事会薪酬与考核委员会第一次会议、审 计委员会第五次会议审议通过。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2、审议通过《关于变更公司住所及修改<公司章程>并办理工商 变更登记的议案》，董事会同意变更公司住所及修改《公司章程》事 项，并提请股东会授权公司经营层办理变更公司住所及修改《公司章 程》工商变更登记手续（最终以市场监督管理局核准的内容为准）。 《公司章程》修改情况如下： | 序号 | 修改前 | 修改后 | | --- | --- | --- | | | 第五条 公司住所：浙江省绍兴市 | 第五条 公司住所：浙江省绍兴市越 | | 1 | 越城区皋埠街道皋北工业区，邮编： | 城区皋埠街道香积路 55 号，邮编： | | | 312035。 | 312035 ...

全球创可贴市场规模总体调查及预测 PART.0 1 根据 QYR esearch （恒州博智）的最新研究数据，全球创可贴市场在 2024 年实现销售额 23.30 亿美元，预计到 2031 年将增长至 34.50 亿美 元，年复合增长率（ CAGR ）达到 6.15% 。整体来看，创可贴行业在全球医疗消费品领域仍保持稳定增长势头，其市场扩张主要受益于消 费者健康意识提升、家庭医疗普及以及新型功能性创可贴产品的持续创新。 创可贴（ Band-Aid ）是一种用于轻微割伤、擦伤等表浅伤口的常用外用敷料，通常由透气胶布、吸收性棉垫和防粘层组成。其作用是保护 伤口，防止细菌感染，减少出血，并有助于愈合过程。现代创可贴种类多样，包含防水型、抗菌型、液体型、儿童图案型等，是应急处理小 伤口的便捷护理用品。 从区域结构来看，欧洲目前是全球最大的创可贴消费市场， 2024 年占全球总消费的 32.60% ，北美紧随其后，占比 30.19% ，中国以 11.06% 的份额位列第三。与欧美市场相比，中国市场的增长潜力更为显著。尽管单价相对较低，但随着居民消费升级、医疗卫生水平提高以及电商 渠道的快速发展，中国市场预计在 2031 ...

近5日融资融券数据一览见下表： 证券之星消息，截至2025年12月10日收盘，振德医疗(603301)报收于72.37元，下跌2.28%，换手率 2.64%，成交量7.02万手，成交额5.04亿元。 12月10日的资金流向数据方面，主力资金净流出3120.74万元，占总成交额6.19%，游资资金净流入 1403.95万元，占总成交额2.79%，散户资金净流入1716.79万元，占总成交额3.41%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-10 | 72.37 | -2.28% | -3120.74万 | -6.19% | 1403.95万 | 2.79% | 1716.79万 | 3.41% | | 2025-12-09 | 74.06 | 0.07% | 1.06亿 | 12.01% | -5365.29万 | -6.05% | -5281.40万 | -5.96% ...

中国经济网北京12月5日讯振德医疗（603301）(603301.SH)今日收报69.20元，跌幅5.99%。 华创证券有限责任公司研究员郑辰、李婵娟、陈俊威12月4日发布研报《振德医疗2025年三季报点评： 利润增速阶段性承压于高基数并购打开成长新空间》称，维持振德医疗"强推"评级。 ...

5股今日获机构给予买入评级 今日（12月4日）A股三大指数涨跌不一。市场全天成交额1.56万亿元，较前一交易日缩量超1200亿元；收盘上涨个股超1400只，其中收盘股价涨停的有40 只。 盘面上，电机概念领涨，板块内三协电机涨超17%。减速器、国家大基金持股、航空发动机等概念跟涨。海南、旅游及酒店、乳业等概念跌幅居前。 据数据宝统计，今日机构研报共发布5条买入型评级记录，包括振德医疗、新城控股、山西汾酒等。 市场表现方面，机构买入型评级个股今日平均下跌1.37%，表现弱于沪指。跌幅较大的个股有山西汾酒、振德医疗、新城控股，跌幅分别为3.42%、 2.50%、1.42%。 | 代码 | 首桥 | 今日收盘价 | 今日涨跌幅 | 机构净买入 | | --- | --- | --- | --- | --- | | | | (元) | (%) | (万元) | | 002402 | 和而泰 | 53.42 | 10.01 | 32987.34 | | 300250 | 初灵信息 | 31.86 | 20.00 | 8261.61 | | 600343 | 航天动力 | 25.65 | -0.19 | 5852.45 ...

Core Viewpoint - Zhend Medical reported a net profit of 203 million yuan for Q1-Q3 2025, representing a decrease of 33.91%, with Q3 net profit at 75 million yuan, down 48.47% [1] Financial Performance - The revenue showed steady growth, while profits faced temporary pressure due to high base effects [1] - The company is entering the respiratory and anesthesia equipment sector through acquisitions, which opens new growth opportunities [1] Future Outlook - Zhend Medical aims to build a broader and deeper healthcare industry chain to support the development of high-quality medical services [1] - Based on the analysis of the Q3 report, long-tail product optimization, and expense input rhythm, the company is valued at 26.8 billion yuan, with a target price of approximately 101 yuan, maintaining a "strong buy" rating [1]

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 101 CNY, while the current price is 75.50 CNY [3]. Core Insights - The company's revenue for the first three quarters of 2025 reached 3.184 billion CNY, reflecting a growth of 1.88%, while the net profit attributable to shareholders was 203 million CNY, down 33.91% year-on-year [2][3]. - The decline in net profit is attributed to a high base effect from the previous year, where a significant asset disposal contributed approximately 93 million CNY to the net profit [3]. - The company has entered the respiratory and anesthesia equipment sector through the acquisition of Ningbo Shengyu Rui Medical Equipment Co., which is expected to enhance its product offerings and market penetration [3]. Financial Performance Summary - For the first three quarters of 2025, the company reported: - Total revenue of 3.184 billion CNY (+1.88%) - Net profit of 203 million CNY (-33.91%) - Non-recurring net profit of 183 million CNY (-18.79%) [2]. - In Q3 2025, the company achieved: - Revenue of 1.084 billion CNY (+0.10%) - Net profit of 75 million CNY (-48.47%) - Non-recurring net profit of 65 million CNY (+2.00%) [2]. - Financial projections for 2024A to 2027E indicate a gradual increase in total revenue from 4.264 billion CNY in 2024 to 5.332 billion CNY in 2027, with corresponding net profits expected to rise from 385 million CNY to 395 million CNY [2][3]. Valuation Metrics - The projected P/E ratios for 2025E, 2026E, and 2027E are 65, 59, and 52 respectively, while the P/B ratios are expected to be 3.6, 3.4, and 3.3 [2][3]. - The report estimates the company's overall valuation at 26.8 billion CNY based on DCF modeling [3].

Core Viewpoint - Zhendemedical has shown significant stock performance with a year-to-date increase of 269.26%, indicating strong market interest and potential growth in the medical supplies sector [1][2]. Financial Performance - For the period from January to September 2025, Zhendemedical reported a revenue of 3.184 billion yuan, reflecting a year-on-year growth of 1.88%. However, the net profit attributable to shareholders decreased by 33.91% to 203 million yuan [2]. - The company has distributed a total of 1.46 billion yuan in dividends since its A-share listing, with 706 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 25, Zhendemedical's stock price reached 78.80 yuan per share, with a market capitalization of 20.996 billion yuan. The stock experienced a net inflow of 26.7841 million yuan from major funds [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) four times this year, with the latest appearance on November 17, where it recorded a net buy of 329,100 yuan [1]. Shareholder Information - As of September 30, 2025, Zhendemedical had 23,600 shareholders, an increase of 4.06% from the previous period. The average number of circulating shares per shareholder decreased by 3.90% to 11,308 shares [2][3]. - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 3.9382 million shares, which is an increase of 190,000 shares from the previous period [3].

Core Points - Zhendemedical (603301) closed at 77.25 yuan on November 24, 2025, with a market capitalization of 20.583 billion yuan, reflecting a 2.33% increase from the previous trading day [1] - The stock opened at 75.27 yuan, reached a high of 77.29 yuan, and a low of 74.39 yuan, with a trading volume of 4.91 billion yuan and a turnover rate of 2.42% [1] Company Actions - Zhendemedical announced the implementation of a partial share repurchase and cancellation related to its first employee stock ownership plan, due to unmet performance targets for the third unlocking period [1] - The company decided to repurchase and cancel 615,667 shares at a price of 25.16 yuan per share, funded by its own resources [1] - This repurchase and cancellation were completed on November 27, 2025, reducing the total share capital from 266,451,202 shares to 265,835,535 shares [1] - The action does not affect the company's financial status, operating results, or listing status, and does not harm the interests of the company and its shareholders [1]

证券日报网讯 11月24日晚间，振德医疗发布公告称，鉴于公司第一期员工持股计划第三个解锁期公司 层面业绩考核指标未达成，对应的员工持股计划未能解锁的615，667股公司股份由公司进行回购注销。 注销日期：2025年11月27日。 （文章来源：证券日报） ...